Cerulean Announces CRLX101 Poster Presentations at the 2015 American Society for Clinical Oncology (ASCO) Annual Meeting

Cerulean Pharma Inc. (Nasdaq:CERU), today announced that four abstracts on its lead candidate, CRLX101, are included in the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago from May 29 through June 2.

CRLX101 in combination with Avastin® (bevacizumab) in metastatic renal cell carcinoma full results
Title: HIF inhibition in metastatic renal cell carcinoma (mRCC): Final results of a phase Ib/IIa clinical trial evaluating the nanoparticle drug conjugate (NDC), CRLX101, in combination with bevacizumab (bev)
Poster Session: Monday, June 1 - 1:15 – 4:45 pm CT
Session Title: Genitourinary (Nonprostate) Cancer
Abstract Number: 4543
Poster Board Number: 216
Location: S Hall A
Presenter: Stephen Keefe, M.D., Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

CRLX101 in combination with Avastin in metastatic renal cell carcinoma versus standard of care trial in progress
Title:Randomized phase 2 study to assess the safety and efficacy of CRLX101 in combination with bevacizumab in patients (pts.) with metastatic renal cell carcinoma (RCC) versus standard of care (SOC)
Poster Session: Monday, June 1 - 1:15 – 4:45 pm CT
Session Title: Genitourinary (Nonprostate) Cancer
Abstract Number: TPS4579
Poster Board Number: 248b
Location: S Hall A
Presenter: Martin Voss, M.D., Memorial Sloan Kettering Cancer Center, New York, NY

CRLX101 in combination with chemoradiotherapy (CRT) in rectal cancer trial in progress
Title: Phase IB/II study of neoadjuvant chemoradiotherapy with CRLX101 and capecitabine for locally advanced rectal cancer
Poster Session: Monday, June 1 - 8:00 – 11:30 am CT
Session Title: Gastrointestinal (Colorectal) Cancer
Abstract Number: TPS3629
Poster Board Number: #117b
Location: S Hall A
Presenter: Andrew Wang, M.D., Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, NC

CRLX101 in combination with Avastin in recurrent platinum resistant ovarian cancer trial in progress
Title: Targeting VEGFRi resistance through HIF-1α suppression: Phase II clinical trial evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent platinum resistant ovarian cancer
Poster Session: Saturday, May 30 – 1:15 – 4:45 pm CT
Session Title: Gynecologic Cancer
Abstract Number: TPS5614
Poster Board Number: 167b
Location: S Hall A
Presenter: Carolyn Krasner, M.D., Massachusetts General Hospital, Harvard Medical School, Boston, MA

All of these abstracts can be viewed on the ASCO website www.asco.org.

About CRLX101

CRLX101 is a nanoparticle-drug conjugate (NDC) designed to concentrate in tumors and slowly release its anti-cancer payload, camptothecin, inside tumor cells. CRLX101 inhibits topoisomerase 1 (topo 1), which is involved in cellular replication, and also inhibits hypoxia-inducible factor-1α (HIF-1α), which research suggests is a master regulator of cancer cell survival mechanisms. CRLX101 has shown activity in four different tumor types, both as monotherapy and in combination with other cancer treatments. CRLX101 is currently in Phase 2 clinical development and has been dosed in more than 250 patients and has Fast Track designation in combination with Avastin® in metastatic renal cell carcinoma.

About CRLX301

CRLX301 is a dynamically tumor-targeted NDC designed to concentrate in tumors and slowly release its anti-cancer payload, docetaxel, inside tumor cells. In preclinical studies, CRLX301 delivers up to 10 times more docetaxel into tumors, compared to an equivalent milligram dose of commercially available docetaxel and was superior to docetaxel in seven of seven animal models, with a statistically significant survival benefit seen in five of those seven models. In addition, preclinical data show that CRLX301 had lower toxicity than has been reported with docetaxel in similar preclinical studies. CRLX301 is currently in Phase 1 clinical development.

About Cerulean Pharma

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial. For more information, please visit www.ceruleanrx.com.

About Cerulean’s Dynamic Tumor Targeting™ Platform

Cerulean’s Dynamic Tumor Targeting Platform creates NDCs that are designed to provide safer and more effective cancer treatments. We believe our NDCs concentrate their anti-cancer payloads inside tumors while sparing normal tissue because they are small enough to pass through the “leaky” vasculature present in tumors but are too large to pass through the wall of healthy blood vessels. Once inside tumors, our NDCs enter tumor cells where they slowly release anti-cancer payloads from within the tumor cells.

Cautionary Note on Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements about the clinical development of our product candidates and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2015, and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.

Avastin® is a trademark of Genentech, Inc.